Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 10, 2007 Brian Lawler	Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result.
The Motley Fool April 2, 2008 Brian Lawler	Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders.
The Motley Fool September 14, 2010 Brian Orelli	This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline.
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool January 6, 2011 Brian Orelli	$145 Million Down; Billions to Go Seattle Genetics signs up another partner.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
The Motley Fool July 5, 2011 Luke Timmerman	Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool January 22, 2008 Brian Lawler	Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering.
The Motley Fool March 31, 2011 Brian Orelli	Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles.
The Motley Fool September 27, 2010 Brian Orelli	Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin.
The Motley Fool July 12, 2011 Luke Timmerman	Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
Bio-IT World May 19, 2004 Barbara Depompa	Surging in Seattle Laid-back coastal-mountain lifestyle bolsters Northwestern biotech company.
The Motley Fool July 13, 2011 Brian Orelli	2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin.
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool October 12, 2010 Brian Orelli	This Drugmaker Stands on a Platform Above the Rest ImmunoGen signs up another partner.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool October 31, 2005 Charly Travers	A Myriad of Shares Management's predilection for excessive share dilution at Myriad Genetics is troubling for investors.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool August 23, 2005 W.D. Crotty	A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look?
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool January 3, 2007 Brian Lawler	Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note.
The Motley Fool April 8, 2011 Brian Orelli	ImmunoGen's Hot Start ImmunoGen scores some positive data, but were investors expecting less?
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool January 19, 2007 Stephen Albainy-Jenei	The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool March 17, 2008 Brian Lawler	Genentech Takes Center Stage There might be more partnerships in store for this drugmaker.
The Motley Fool August 5, 2009 Brian Orelli	Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool November 17, 2006 Brian Lawler	Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note.
BusinessWeek July 31, 2006 Gene G. Marcial	Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street.
The Motley Fool April 8, 2011 Brian Orelli	A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals.
BusinessWeek October 6, 2003 Arlene Weintraub	Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science."
The Motley Fool September 11, 2006 Brian Lawler	More Work on Cancer Drug for Genentech The FDA asks for more data about Avastin, which could be used to treat various cancers. Investors, take note.
The Motley Fool January 11, 2005 W.D. Crotty	Genentech's Pricey DNA The company continues to churn out sales and earnings gains, but it looks richly priced.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.